HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Kishi, K. Articles by Yoshimura, K. Search for Related Content PubMed PubMed Citation Articles by Kishi, K. Articles by Yoshimura, K.

Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions

¹ Dept of Respiratory Medicine, Respiratory Center, Toranomon Hospital, and ² Dept of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan

CORRESPONDENCE: K. Kishi, Dept of Respiratory Medicine, Respiratory Center, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. Fax: 81 335827068. E-mail: kazumak@toranomon.gr.jp

Keywords: Doxorubicin, lung cancer, malignant pleural effusion, OK-432, pleurodesis

Received: December 12, 2003
Accepted February 29, 2004

Malignant pleural effusion develops frequently in patients with advanced lung cancer. Chemical pleurodesis is the most effective palliative treatment for these patients.

The efficacy of pleurodesis using both OK-432, a preparation of Streptococcus pyogenes, and doxorubicin for 20 patients with cytology-proven malignant pleural effusion associated with lung cancer was evaluated. After complete removal of pleural effusion, OK-432 and 30 mg of doxorubicin were injected via an inserted chest tube. Treatment was terminated when the volume of daily drainage reached <200 mL. If the daily volume remained >200 mL, an additional OK-432 was administered every 3 days.

In total, 16 patients (80%) revealed a complete response, two patients (10%) revealed a partial response, and no response was seen in two patients. Eighteen patients with complete or partial responses did not show subsequent reaccumulation of pleural effusion after pleurodesis. The chest tube remained in place for an average of 6.4 days, draining a mean of 2,854 mL. The main side-effects were fever and pain that were easily treated with nonsteroidal anti-inflammatory drugs.

Pleurodesis using both OK-432 and doxorubicin showed high efficacy for controlling malignant pleural effusions caused by lung cancer.

This article has been cited by other articles:

				H. E Davies, Y C G. Lee, and R. J O Davies Pleurodesis for malignant pleural effusion: talc, toxicity and where next? Thorax, July 1, 2008; 63(7): 572 - 574. [Full Text] [PDF]

				T. Laisaar, V. Palmiste, T. Vooder, and T. Umbleja Life expectancy of patients with malignant pleural effusion treated with video-assisted thoracoscopic talc pleurodesis Interactive CardioVascular and Thoracic Surgery, June 1, 2006; 5(3): 307 - 310. [Abstract] [Full Text] [PDF]

				O. Dikensoy, Z. Zhu, E. Donnelly, G. T. Stathopoulos, K. B. Lane, and R. W. Light Combination Therapy With Intrapleural Doxycycline and Talc in Reduced Doses Is Effective in Producing Pleurodesis in Rabbits Chest, November 1, 2005; 128(5): 3735 - 3742. [Abstract] [Full Text] [PDF]